San Antonio, TX Clinical Trials Report — May 2026

For San Antonians interested in contributing to medical science, May 2026 brings both immediate opportunities and a fresh wave of new research studies. With 964 clinical trials currently recruiting across 537 research facilities in the city, there are numerous ways to participate.

Time is of the essence for many studies, as 61 clinical trials in San Antonio are slated to conclude enrollment within the next 90 days. This includes opportunities for healthy volunteers, with 8 trials actively seeking participants without specific health conditions before their deadlines.

Urgent Opportunities: Trials Nearing Close

Patients with specific health conditions should note the impending deadlines for several important research areas. Conditions with trials closing soon include:

• Advanced solid tumor (8 trials)
• Non-small cell lung cancer (3 trials)
• Metastatic cancer (3 trials)
• Irritable bowel syndrome with constipation (IBS-C) (2 trials)
• Type 2 diabetes (2 trials)
• Tumor, solid (2 trials)
• Hepatic impairment (2 trials)
• Cirrhosis, liver (2 trials)
• Amyotrophic lateral sclerosis (2 trials)

These trials offer a chance to access potential new treatments and contribute to understanding these conditions before their enrollment windows close.

New Research Horizons in San Antonio

This month, San Antonio welcomed 20 new clinical trials, a slight increase from the 19 trials that opened in April 2026. These new studies span a variety of health areas, with a strong focus on metabolic health and oncology.

Several notable new trials from major sponsors are now recruiting in San Antonio:

• Novo Nordisk A/S is sponsoring a significant Phase 3 study, NCT07567001, "A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity." This large trial aims to enroll 5,610 participants to evaluate the safety and effectiveness of a new compound for individuals with heart failure and excess body weight.
• Another Phase 3 study from Novo Nordisk A/S, NCT07564414, "A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight," is seeking 2,500 participants to assess the efficacy of CagriSema for weight loss.
• Eli Lilly and Company has launched NCT07589608, a Phase 2 study titled "A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight." This trial aims for 400 participants to explore new options for weight management.
• Also from Eli Lilly and Company, NCT07589595 is a Phase 2 study investigating "Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)." This study is designed for 350 participants to evaluate if donanemab can slow the progression of cognitive and functional decline.
• The Ohio State University is sponsoring NCT07567040, a Phase 3 trial called "Delaying the Onset of Nearsightedness Until Treatment (DONUT) Clinical Trial." This study involves 664 participants and will test whether atropine drops can delay the onset of nearsightedness in children.
• The Canopy Cancer Collective, LLC is leading NCT07605702, an observational "Clinical Registry Protocol" aiming for 100,000 participants to collect comprehensive data on gastrointestinal cancer patients.

The most common conditions addressed by new trials this month include obesity (5 trials), overweight (3 trials), locally advanced (unresectable) or metastatic solid tumors (2 trials), and obstructive sleep apnoea (2 trials). Drug trials constitute the majority of new studies, with 16 new drug trials opening.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, San Antonio offers several ways to contribute to research. Of the 20 new trials launched this month, 2 are actively seeking healthy volunteers. Overall, a total of 85 clinical trials are currently recruiting healthy participants in San Antonio, providing numerous opportunities to support medical advancements.

San Antonio's Leading Research Facilities

San Antonio is home to a robust network of research institutions that consistently lead in clinical trial activity. These facilities are key destinations for individuals seeking to participate in medical research:

• The University of Texas Health Science Center at San Antonio (including UT Health San Antonio) (129 trials)
• NEXT Oncology (53 trials)
• Research Site (38 trials)
• Children's Hospital of San Antonio (32 trials)
• Methodist Children's Hospital of South Texas (24 trials)
• START San Antonio (20 trials)
• Texas Dermatology and Laser Specialists (13 trials)
• GSK Investigational Site (12 trials)
• Texas Oncology - San Antonio (12 trials)
• Endeavor Clinical Trials (11 trials)

These institutions offer a broad spectrum of research, from comprehensive medical studies at UT Health San Antonio, to specialized oncology research at NEXT Oncology and START San Antonio, and pediatric care at Children's Hospital of San Antonio and Methodist Children's Hospital of South Texas.

Expanding Your Search: Nearby Texas Cities

While San Antonio provides extensive clinical trial opportunities, individuals may also consider options in other major Texas cities. Nearby communities with active trials include Houston (45 trials), Dallas (31 trials), and Austin (16 trials), as well as McAllen (4 trials), El Paso (4 trials), Fort Worth (4 trials), Plano (3 trials), and Amarillo (3 trials).

Participation in clinical trials is open to a diverse range of individuals. Of the 20 new trials launched this month, 16 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 3 new trials include children. Industry sponsors, such as Novo Nordisk A/S (4 trials) and Eli Lilly and Company (2 trials), are driving a significant portion of new research efforts this month.

As San Antonio continues to grow as a vital center for medical innovation, the opportunities for patients and healthy volunteers to contribute to the future of healthcare remain strong and diverse.